Inverse link found for antioxidant levels, all-cause dementia
May 04, 2022
Serum lutein+zeaxanthin and β-cryptoxanthin levels were inversely associated with incident all-cause dementia.
Medicare will only cover Aduhelm for patients in clinical trials
Apr 08, 2022
The decision is meant to protect patients while gathering more clinical data on whether the medication actually helps slow declines in thinking.
Medicare spending spikes for dementia diagnoses in seniors
Jun 13, 2022
Medicare spending was higher for adults with a formal clinical diagnosis of dementia versus a positive screening for cognitive impairment.
Medicare policy changes tied to drop in hospice use for dementia
May 09, 2022
Immediate and lasting reductions were seen in the share of patients receiving hospice care with the Alzheimer’s disease and related dementia code.
Alzheimer’s disease, related dementia diagnoses up in Medicare decedents
Apr 01, 2022
The percentage of older U.S. decedents with a diagnosis of Alzheimer’s disease and related dementias increased significantly from 2004 to 2017.
Most with Alzheimer’s disease, mild cognitive impairment would have been excluded from aducanumab...
Sep 16, 2021
Overall, 92.2, 91, and 85.5% of Medicare beneficiaries with Alzheimer’s disease-related disorders, Alzheimer’s disease, and mild cognitive impairment met at least one of the exclusion criteria.
Aortic valve replacement up in patients with Alzheimer’s disease
Sep 17, 2021
One-year outcomes were similar for patients with or without Alzheimer’s disease and related dementias.
Excess mortality seen for seniors with Alzheimer’s disease, dementia in COVID-19
Mar 08, 2022
Enrollees with Alzheimer’s disease and related dementias had increased adjusted mortality, especially for Asian, Black and Hispanic populations.
App-based protocol ID’s delirium in hospitalized adults
Nov 08, 2021
Overall accuracy of two-step protocol including two-item screen and 3-minute diagnostic assessment was 89%, 87% for nurses, doctors.
Relapse risk for psychosis in dementia lower with continued pimavanserin
Jul 22, 2021
The findings were seen in a double-blind, randomized, placebo-controlled discontinuation trial that was stopped early for efficacy.